AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$144.43
+0.68%Year over year
Reported trailing growth
- Revenue
- +56.9%
- EBITDA
- +22.9%
- EBIT
- +17.6%
- EPS
- +26.0%
- Free cash flow
- +40.9%
- Operating cash flow
- +40.9%
Forward estimates
Based on analyst estimates
- Revenue
- +69.3%
- EBITDA
- +156.4%
- EPS
- +133.2%
Three-year CAGR
- Revenue
- +133.7%
- EBITDA
- +38.3%
- EBIT
- +39.7%
- Net income
- +36.2%
- EPS
- +38.6%
- Free cash flow
- +27.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026